These results suggest that targeting Oct1 and its associated upstream and downstream pathways (such as the cofactor OCA-B) may be of therapeutic benefit in autoimmunity while sparing viral pathogen-directed immune function. The gene discussed is POU2AF1; the disease is Autoimmunity.